Smart treatment strategies for alleviating tauopathy and neuroinflammation to improve clinical outcome in Alzheimer's disease

• Published in: Drug discovery today 2020-12, Vol.25 (12), p.2110-2129
• Main Authors: Tatiparti, Katyayani, Sau, Samaresh, Rauf, Mohd Ahmar, Iyer, Arun K.
• Format: Article
• Language: English
• ISSN: 1359-6446; 1878-5832
• DOI: 10.1016/j.drudis.2020.09.025

•Alzheimer's disease (AD) is a complex condition with several comorbidities.•The understanding of the disease even after much research is still inconclusive.•Treatment options are very limited requiring new discoveries.•Reliable therapeutic regimen is the need of the hour.•New medications, treatment regimen and targeted delivery systems together could achieve the goal of curing AD. Alzheimer's disease (AD) is a complex neurodegenerative disease leading to progressive loss of memory that mainly affects people above 60 years of age. It is one of the leading causes of deaths in the USA. Given its inherent heterogeneity and a still-incomplete understanding of its pathology, biomarkers, and targets available for therapy, it is a challenge to design an effective therapeutic strategy. Several hypotheses have been proposed to understand the disease and to identify reliable markers and targets for treatments. However, none have resulted in strong support from clinical trials. In this review, we objectively discuss the various therapeutic strategies and mechanistic approaches to improve the current clinical outcome of AD therapy. There is a significant lack of understanding still of Alzheimer's disease lacks despite extensive research. Effective therapy with blood–brain barrier-penetrating drugs/delivery systems and successful disease-modulating strategies are unmet needs to improve the quality of life of patients.